{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T07:02:25Z","timestamp":1793257345001,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["U54 GM115458"],"award-info":[{"award-number":["U54 GM115458"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jtct.2024.12.002","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T02:27:15Z","timestamp":1733970435000},"page":"71.e1-71.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6261-4898","authenticated-orcid":false,"given":"Moataz","family":"Ellithi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9574-3496","authenticated-orcid":false,"given":"Magdi","family":"Elsallab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Lunning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9342-5635","authenticated-orcid":false,"given":"Sarah A.","family":"Holstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smriti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7830-1792","authenticated-orcid":false,"given":"Jonathan Q.","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4761-9607","authenticated-orcid":false,"given":"Jihyun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7578-0393","authenticated-orcid":false,"given":"Marcela V.","family":"Maus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Frigault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"D'Angelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2024.12.002_bib0001","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1146\/annurev-pharmtox-031720-102211","article-title":"Pharmacology of chimeric antigen receptor-modified T cells","volume":"61","author":"Song","year":"2021","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"8","key":"10.1016\/j.jtct.2024.12.002_bib0002","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering CAR-T cells: design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol"},{"key":"10.1016\/j.jtct.2024.12.002_bib0003","unstructured":"FDA. FDA approval brings first gene therapy to the United States. 2017. Accessed January 12, 2024.` https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approval-brings-first-gene-therapy-united-states."},{"issue":"25","key":"10.1016\/j.jtct.2024.12.002_bib0004","doi-asserted-by":"crossref","first-page":"3225","DOI":"10.1182\/blood-2016-01-691162","article-title":"APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment","volume":"127","author":"Tai","year":"2016","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2024.12.002_bib0005","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2024.12.002_bib0006","unstructured":"FDA. FDA approves idecabtagene vicleucel for multiple myeloma. Accessed January 12, 2024.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-idecabtagene-vicleucel-multiple-myeloma."},{"issue":"10297","key":"10.1016\/j.jtct.2024.12.002_bib0007","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet"},{"key":"10.1016\/j.jtct.2024.12.002_bib0008","unstructured":"FDA. FDA approves ciltacabtagene autoleucel for relapsed or refractory multiple myeloma. Accessed January 12, 2024.https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-ciltacabtagene-autoleucel-relapsed-or-refractory-multiple-myeloma."},{"issue":"4","key":"10.1016\/j.jtct.2024.12.002_bib0009","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2024.12.002_bib0010","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2024.12.002_bib0011","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1016\/j.jtct.2024.12.002_bib0012","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.jtct.2024.12.002_bib0013","doi-asserted-by":"crossref","first-page":"682","DOI":"10.3324\/haematol.2023.283296","article-title":"Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells","volume":"109","author":"Kathari","year":"2023","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.jtct.2024.12.002_bib0014","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/bcp.13098","article-title":"The value of patient reporting to the pharmacovigilance system: a systematic review","volume":"83","author":"In\u00e1cio","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.jtct.2024.12.002_bib0015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00228-008-0475-9","article-title":"Pharmacovigilance: methods, recent developments and future perspectives","volume":"64","author":"H\u00e4rmark","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtct.2024.12.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024024166","article-title":"Second primary malignancies after commercial CAR T cell therapy: analysis of FDA adverse events reporting system (FAERS)","author":"Elsallab","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2024.12.002_bib0017","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/pds.3395","article-title":"Evaluation of FDA safety-related drug label changes in 2010","volume":"22","author":"Lester","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.jtct.2024.12.002_bib0018","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/pds.3317","article-title":"Post-market drug safety evidence sources: an analysis of FDA drug safety communications","volume":"21","author":"Ishiguro","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jtct.2024.12.002_bib0019","unstructured":"FAERS Quarterly Data Extract Files. Accessed February 20, 2024.https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/ FPD-QDE-FAERS.html."},{"key":"10.1016\/j.jtct.2024.12.002_bib0020","unstructured":"Medical Dictionary for Regulatory Activities (MedDRA\u00ae). Available at: https:\/\/www.meddra.org\/how-to-use\/support-documentation\/english\/welcome."},{"key":"10.1016\/j.jtct.2024.12.002_bib0021","unstructured":"The U.S. Food and Drug Administration. Postmarketing safety reporting for human drug and biological products including vaccines. Accessed April 29, 2024.https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/postmarketing-safety-reporting-human-drug-and-biological-products-including-vaccines. 2020."},{"issue":"1","key":"10.1016\/j.jtct.2024.12.002_bib0022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.jtct.2024.12.002_bib0023","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.jtct.2024.12.002_bib0024","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.jtct.2024.12.002_bib0025","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jtct.2024.12.002_bib0026","unstructured":"The U.S. Food and Drug Administration. Good pharmacovigilance practices and pharmacoepidemiologic assessment. Accessed April 24, 2024. Available at:https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/good-pharmacovigilance-practices-and-pharmacoepidemiologic-assessment. 2020"},{"issue":"14","key":"10.1016\/j.jtct.2024.12.002_bib0027","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.jtct.2024.12.002_bib0028","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.2023021429","article-title":"Chemotherapy-induced reversal of ciltacabtagene autoleucel\u2013associated movement and neurocognitive toxicity","volume":"142","author":"Graham","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2024.12.002_bib0029","first-page":"1","article-title":"Targeting TGF\u03b2-activated kinase-1 activation in microglia reduces CAR T immune effector cell-associated neurotoxicity syndrome","author":"Vinnakota","year":"2024","journal-title":"Nat Cancer"},{"issue":"2","key":"10.1016\/j.jtct.2024.12.002_bib0030","first-page":"S380","article-title":"Clinical experience with cranial nerve impairment in the Cartitude-1, Cartitude-2 Cohorts a, B and C, and Cartitude-4 studies of Ciltacabtagene Autoleucel (Cilta-cel)","volume":"30","author":"van de Donk","year":"2024","journal-title":"Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2024.12.002_bib0031","first-page":"1","article-title":"Role of CXCL10 in central nervous system inflammation","volume":"6","author":"Michlmayr","year":"2014","journal-title":"Int J Interferon Cytokine Mediat Res"},{"issue":"4","key":"10.1016\/j.jtct.2024.12.002_bib0032","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/ana.24494","article-title":"A destructive feedback loop mediated by CXCL10 in central nervous system inflammatory disease","volume":"78","author":"Roberts","year":"2015","journal-title":"Ann Neurol"},{"issue":"7","key":"10.1016\/j.jtct.2024.12.002_bib0033","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3324\/haematol.2022.282053","article-title":"Driving CARs to new places: locally produced BCMA CAR T cells to treat multiple myeloma","volume":"108","author":"Sj\u00f6strand","year":"2023","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.jtct.2024.12.002_bib0034","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"10.1016\/j.jtct.2024.12.002_bib0035","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/bloodadvances.2020004079","article-title":"Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy","volume":"6","author":"Kambhampati","year":"2022","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2024.12.002_bib0036","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1182\/blood-2022-170404","article-title":"Immune recovery post BCMA CAR-T: implications for infection prophylaxis and vaccinations","volume":"140","author":"Richard","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2024.12.002_bib0037","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1093\/annonc\/mdw606","article-title":"Second primary malignancies in multiple myeloma: an overview and IMWG consensus","volume":"28","author":"Musto","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2024.12.002_bib0038","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S1470-2045(13)70609-0","article-title":"Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data","volume":"15","author":"Palumbo","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2024.12.002_bib0039","unstructured":"CARVYKTI Ciltacabtagene autoleucel. Package insert. Janssen Biotech, Inc. Accessed May 21, 2024. Available at: https:\/\/www.fda.gov\/media\/156560\/download."},{"issue":"6","key":"10.1016\/j.jtct.2024.12.002_bib0040","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1200\/JCO.22.00842","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-Cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","volume":"41","author":"Martin","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.jtct.2024.12.002_bib0041","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1001\/jamainternmed.2019.3066","article-title":"Association between data sources and US Food and Drug Administration Drug Safety Communications","volume":"179","author":"Tau","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"2","key":"10.1016\/j.jtct.2024.12.002_bib0042","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.clinthera.2020.12.011","article-title":"Review of FDA Amendments Act Section 921 experience in posting data-mining results from the FAERS database","volume":"43","author":"Beninger","year":"2021","journal-title":"Clin Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724008030?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636724008030?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:51:38Z","timestamp":1788987098000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636724008030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2666636724008030"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2024.12.002","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2024.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}